Source comparison
CJC-1295 no DAC & Ipamorelin Synergistic GH Release Research: Protocol Comparison
The following table compares single-peptide protocols against combination therapy based on documented preclinical pharmacology: CJC-1295 no DAC monotherapy (1mg 2×/week) 80–120% Minimal increase 150–200% increase Moderate (sustained GHRH receptor occupancy) Ef
This comparison does not assign a generated winner or score.
- The following table compares single-peptide protocols against combination therapy based on documented preclinical pharmacology:
- CJC-1295 no DAC monotherapy (1mg 2×/week)
- 80–120%
- Minimal increase
- 150–200% increase
- Moderate (sustained GHRH receptor occupancy)
- Effective for extending pulse duration but limited by feedback suppression at higher doses
- Ipamorelin monotherapy (250mcg 2×/day)
- 100–150%
- 100% increase (doubles pulse count)
- 50–80% increase
- Low (short half-life limits cumulative exposure)
- Excellent for increasing pulse frequency without cortisol elevation; limited amplitude per pulse
- CJC-1295 no DAC + Ipamorelin (1mg 2×/week + 250mcg 2×/day)
- 300–450%
- 100% increase
- 200–300% increase
- Low-Moderate (intermittent ghrelin stimulation resets feedback)
- Synergistic protocol produces non-linear GH elevation through dual-pathway activation; requires precise dosing and reconstitution